FDA Approves Heart Valve Procedure Tested at Fletcher Allen and UVM

FDA Approves Heart Valve Procedure Tested at Fletcher Allen and UVM

The Food and Drug Administration (FDA) approved a heart valve procedure tested at Fletcher Allen and UVM.
BURLINGTON, Vt. - The Food and Drug Administration (FDA) approved a heart valve procedure tested at Fletcher Allen and UVM.

Fletcher Allen says the procedure tested during a clinical trial replaced heart valves using catheters instead of open heart surgery. The procedure called Transcatheter Aortic Valve Replacement (TAVR) have been added to the American Heart Association and American College of Cardiology guidelines.

“TAVR is truly a lifesaving treatment and we’re very pleased the Fletcher Allen heart team was involved in determining its effectiveness,” said Harry Dauerman, M.D., an interventional cardiologist at Fletcher Allen and professor at the UVM College of Medicine. “It’s a great example of the value of having an academic medical center in our region – we not only have the expertise and resources to deliver the most advanced treatments, but we are also involved in developing them.”

Fletcher Allen and UVM are currently enrolling patients in a national, randomized clinical trial comparing the safety and effectiveness of TAVR versus standard surgery in these lower risk patients. For more information on this trial, contact the Cardiology Research office at (802)-847-4746.
Page: [[$index + 1]]
comments powered by Disqus